Approximately 25%–50% of individuals with RUNX1-FPDMM will develop malignancy (9, 13, 14), mainly MDS and AML and less frequently acute lymphoblastic leukemia (ALL) or lymphoma or other hematologic malignancies. Here, RUNX1 is linked to hematologic disorder.